サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1644166

臨床試験における人工知能の世界市場

Artificial Intelligence in Clinical Trials

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
臨床試験における人工知能の世界市場
出版日: 2025年01月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

臨床試験における人工知能の世界市場は2030年までに35億米ドルに到達

2024年に16億米ドルと推定される臨床試験における人工知能の世界市場は、分析期間2024-2030年にCAGR 14.0％で成長し、2030年には35億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである臨床試験AIソフトウェアは、CAGR13.3%を記録し、分析期間終了までに19億米ドルに達すると予測されます。臨床試験AIサービス分野の成長率は、分析期間でCAGR 14.8%と推定されます。

米国市場は4億2,060万米ドルと推定、中国はCAGR13.2％で成長予測

米国の臨床試験における人工知能市場は、2024年に4億2,060万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを13.2%として、2030年までに5億4,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.8%と12.1%と予測されています。欧州では、ドイツがCAGR 10.3%で成長すると予測されています。

世界の臨床試験における人工知能市場- 主要動向と促進要因まとめ

AIは臨床試験をどのように変革するか？

人工知能（AI）は、効率を高め、コストを削減し、成果を向上させることで、臨床試験の状況に革命をもたらしています。従来の臨床試験は多くの場合、時間とコストがかかり、患者募集やデータ収集の遅れなど非効率がつきものでした。AIは、機械学習アルゴリズム、自然言語処理（NLP）、予測分析を活用して臨床試験プロセスを合理化することで、こうした課題に対処します。

患者募集では、AIシステムが電子カルテ（EHR）、遺伝子データ、その他のデータセットを分析し、治験基準を満たす適格な候補者を特定します。これにより、募集スケジュールが短縮され、より多様で代表的な参加者プールが確保されます。AIはまた、過去のデータを分析して最も効果的なプロトコル、エンドポイント、調査手法を予測することで、試験デザインを最適化します。

臨床試験中、AIを搭載したプラットフォームは、患者の反応モニタリングを自動化し、異常をリアルタイムで特定することで、データ収集と分析を強化します。これらのツールにより迅速な意思決定が可能になり、スポンサーはプロトコルを調整し、試験効率を向上させることができます。臨床試験のワークフローにおける重要なボトルネックに対処することで、AIは臨床研究開発に変革をもたらしつつあります。

臨床試験におけるAI導入の原動力とは？

臨床試験の複雑化が、この領域におけるAI導入の大きな推進力となっています。プレシジョン・メディシンと個別化治療の台頭により、臨床試験にはより詳細なデータと、被験者募集とモニタリングに対する個別化されたアプローチが必要になっています。AIシステムは、こうした複雑なデータセットの管理と解釈に必要な計算能力と分析能力を提供し、臨床試験の成功を確実にします。

医薬品開発コストの増大も重要な要因の一つです。製薬業界では平均して、研究開発費のかなりの部分を臨床試験が占めています。AIを搭載したツールは、治験実施施設の選定、データ分析、規制当局への報告など、労働集約的な作業を自動化することでコストを削減します。この効率化により、スポンサーはリソースをより効果的に配分し、医薬品をより早く市場に投入することができます。

さらに、実世界のエビデンスを求める需要が、市販後臨床試験や観察研究におけるAIの採用を後押ししています。AIツールは、患者登録や請求データベースなどの実データを分析し、治療法の長期的な安全性と有効性を評価します。これらの機能は、エビデンスに基づく意思決定を重視する規制動向と合致しており、臨床試験へのAIの統合をさらに後押ししています。

AIは臨床研究の多様性とアクセシビリティを改善できるか？

AIは、高度なデータ分析や予測モデリングを活用することで、多様性やアクセシビリティといった臨床研究における長年の課題に取り組んでいます。従来の臨床試験では、不特定多数の人々から参加者を集めるのに苦労することが多く、人口統計学的に一般化されない偏った結果につながる可能性があります。AIシステムは、臨床情報とともに社会人口統計データを分析し、多様な参加者を特定してリクルートすることで、より包括的な臨床試験を実現します。

AIを活用したツールは、分散型およびバーチャルな臨床試験モデルを可能にすることで、臨床試験へのアクセスも拡大しています。このようなアプローチにより、参加者が治験実施施設まで足を運ぶ必要性が減り、地方や十分なサービスを受けていない地域の人々も研究にアクセスしやすくなります。AIは遠隔モニタリングとデータ収集を容易にし、参加者が自宅にいながらにして研究に参加できるようにします。この機能は、リクルート率を向上させるだけでなく、全体的な患者体験を向上させる。

さらに、AIは試験データのリアルタイム分析を可能にするため、スポンサーは参加への障壁を特定し、対処することができます。募集戦略を調整し、ロジスティクスの課題を取り除くことで、AIはより公平な臨床研究の展望を育んでいます。こうした進歩は、より代表的でインパクトのある臨床試験への道を開いています。

臨床試験におけるAI市場の成長を促すものは何か？

臨床試験における人工知能市場成長は、臨床研究におけるイノベーションと効率性に対する需要高まりを反映した、いくつか重要な要因によって牽引されています。慢性疾患有病率上昇と個別化治療ニーズ高まりが、複雑な臨床試験設計と実施におけるAI導入に拍車をかけています。AIを搭載したプラットフォームは、リクルートを加速し、プロトコールを最適化し、データ分析を強化することで、現代臨床研究における重要な課題に対処します。

医薬品の迅速な承認や臨床試験プロセスの透明性向上といった消費者行動の動向は、製薬企業にAIソリューションの採用を促しています。AIツールはリアルタイムの報告とモニタリングを可能にし、利害関係者が試験のライフサイクルを通じて情報を得られるようにします。

さらに、臨床研究における先進技術の使用に対する規制当局の支援が、市場の成長を後押ししています。FDAなどの機関は、試験の効率とコンプライアンスを向上させるためにAIの採用を奨励しています。これらの要因が、AIアルゴリズム、データ統合、ウェアラブル技術の進歩と相まって、臨床試験におけるAI市場の急速な拡大を後押しし、医薬品開発と臨床研究における将来のイノベーションの要として位置付けられています。

セグメント

コンポーネント（ソフトウェアコンポーネント、サービスコンポーネント）;アプリケーション（医薬品開発アプリケーション、創薬アプリケーション、臨床試験管理アプリケーション、その他アプリケーション）;最終用途（製薬・バイオテクノロジー企業最終用途、学術・研究機関最終用途、その他最終用途）

調査対象企業の例（全48件）

  • IBM Corporation
  • Insilico Medicine
  • IQVIA, Inc.
  • NVIDIA Corporation
  • Owkin, Inc.
  • Recursion Pharmaceuticals
  • Saama Technologies, LLC
  • Sensyne Health Group Limited

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29255

Global Artificial Intelligence in Clinical Trials Market to Reach US$3.5 Billion by 2030

The global market for Artificial Intelligence in Clinical Trials estimated at US$1.6 Billion in the year 2024, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Clinical Trials AI Software, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Clinical Trials AI Services segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$420.6 Million While China is Forecast to Grow at 13.2% CAGR

The Artificial Intelligence in Clinical Trials market in the U.S. is estimated at US$420.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$545.0 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.8% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Global Artificial Intelligence in Clinical Trials Market - Key Trends & Drivers Summarized

How Is AI Transforming Clinical Trials?

Artificial Intelligence (AI) is revolutionizing the clinical trials landscape by enhancing efficiency, reducing costs, and improving outcomes. Traditional clinical trials are often time-consuming, expensive, and fraught with inefficiencies, such as delays in patient recruitment and data collection. AI addresses these challenges by leveraging machine learning algorithms, natural language processing (NLP), and predictive analytics to streamline trial processes.

In patient recruitment, AI systems analyze electronic health records (EHRs), genetic data, and other datasets to identify eligible candidates who meet trial criteria. This accelerates recruitment timelines and ensures a more diverse and representative participant pool. AI also optimizes trial design by analyzing historical data to predict the most effective protocols, endpoints, and methodologies.

During trials, AI-powered platforms enhance data collection and analysis by automating the monitoring of patient responses and identifying anomalies in real time. These tools enable faster decision-making, allowing sponsors to adjust protocols and improve trial efficiency. By addressing critical bottlenecks in trial workflows, AI is transforming clinical research and development.

What Drives the Adoption of AI in Clinical Trials?

The increasing complexity of clinical trials is a significant driver of AI adoption in this domain. With the rise of precision medicine and personalized therapies, trials require more granular data and tailored approaches to recruitment and monitoring. AI systems provide the computational power and analytical capabilities needed to manage and interpret these complex datasets, ensuring trial success.

The growing cost of drug development is another key factor. On average, clinical trials account for a substantial portion of R&D expenditures in the pharmaceutical industry. AI-powered tools reduce costs by automating labor-intensive tasks, such as site selection, data analysis, and regulatory reporting. This efficiency allows sponsors to allocate resources more effectively and bring drugs to market faster.

Additionally, the demand for real-world evidence is driving the adoption of AI in post-market trials and observational studies. AI tools analyze real-world data, such as patient registries and claims databases, to assess the long-term safety and effectiveness of therapies. These capabilities align with regulatory trends emphasizing evidence-based decision-making, further supporting AI’s integration into clinical trials.

Can AI Improve Diversity and Accessibility in Clinical Research?

AI is addressing longstanding challenges in clinical research, such as diversity and accessibility, by leveraging advanced data analysis and predictive modeling. Traditional clinical trials often struggle to recruit participants from underrepresented populations, leading to biased results that may not generalize across demographics. AI systems analyze socio-demographic data alongside clinical information to identify and recruit diverse participants, ensuring more inclusive trials.

AI-powered tools are also expanding access to clinical trials by enabling decentralized and virtual trial models. These approaches reduce the need for participants to travel to trial sites, making research more accessible to those in rural or underserved areas. AI facilitates remote monitoring and data collection, allowing participants to engage from the comfort of their homes. This capability not only improves recruitment rates but also enhances the overall patient experience.

Moreover, AI enables real-time analysis of trial data, allowing sponsors to identify and address barriers to participation. By tailoring recruitment strategies and removing logistical challenges, AI is fostering a more equitable clinical research landscape. These advancements are paving the way for more representative and impactful clinical trials.

What’s Driving the Growth of the AI in Clinical Trials Market?

The growth in the Artificial Intelligence in Clinical Trials market is driven by several key factors, reflecting the increasing demand for innovation and efficiency in clinical research. The rising prevalence of chronic diseases and the growing need for personalized therapies are spurring the adoption of AI to design and execute complex trials. AI-powered platforms accelerate recruitment, optimize protocols, and enhance data analysis, addressing critical challenges in modern clinical research.

Consumer behavior trends, such as the demand for faster drug approvals and greater transparency in trial processes, are pushing pharmaceutical companies to adopt AI solutions. AI tools enable real-time reporting and monitoring, ensuring that stakeholders remain informed throughout the trial lifecycle.

Furthermore, regulatory support for the use of advanced technologies in clinical research is boosting market growth. Agencies such as the FDA are encouraging the adoption of AI to improve trial efficiency and compliance. These factors, combined with advancements in AI algorithms, data integration, and wearable technologies, are driving the rapid expansion of the AI in Clinical Trials market, positioning it as a cornerstone of future innovation in drug development and clinical research.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software Component, Services Component); Application (Drug Development Application, Drug Discovery Application, Clinical Trial Management Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

  • IBM Corporation
  • Insilico Medicine
  • IQVIA, Inc.
  • NVIDIA Corporation
  • Owkin, Inc.
  • Recursion Pharmaceuticals
  • Saama Technologies, LLC
  • Sensyne Health Group Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Artificial Intelligence in Clinical Trials - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI-Driven Patient Recruitment Solutions Propel Growth in Faster Clinical Trial Enrollments
    • AI for Real-Time Monitoring Expands Opportunities in Decentralized Clinical Trials
    • AI-Powered Biomarker Discovery Drives Adoption in Precision Medicine Trials
    • Integration of AI with EHRs Strengthens Business Case for Streamlined Patient Matching
    • Demand for Cost Optimization Spurs Growth of AI in Trial Management Systems
    • Integration of AI in Wearables Strengthens Opportunities for Remote Patient Monitoring
    • AI in Genomic Analysis Expands Market Potential for Rare Disease Clinical Trials
    • AI for Drug Repurposing Highlights Market Relevance in Accelerating Development Timelines
    • AI for Multilingual Trial Management Expands Accessibility in Global Research Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Clinical Trials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Software Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Software Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Drug Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Drug Discovery Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Clinical Trial Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Clinical Trial Management Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academic and Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Academic and Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Component - Software Component and Services Component - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Artificial Intelligence in Clinical Trials by Component - Percentage Breakdown of Value Sales for Software Component and Services Component for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by Application - Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Artificial Intelligence in Clinical Trials by Application - Percentage Breakdown of Value Sales for Drug Development Application, Drug Discovery Application, Clinical Trial Management Application and Other Applications for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Clinical Trials by End-Use - Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Artificial Intelligence in Clinical Trials by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic and Research Institutes End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION